Cubist Systematic Strategies’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-478,201
| Closed | -$97.4M | – | 2949 |
|
|
2025
Q2 | $88.8M | Buy |
+478,201
| New | +$88.9M | 0.41% | 10 |
|
|
2024
Q1 | – | Sell |
-113,579
| Closed | -$19.6M | – | 3629 |
|
|
2023
Q4 | $17.6M | Buy |
113,579
+111,739
| +6,073% | +$16.3M | 0.11% | 197 |
|
|
2023
Q3 | $274K | Sell |
1,840
-132,338
| -99% | -$19.4M | ﹤0.01% | 2638 |
|
|
2023
Q2 | $18.1M | Buy |
+134,178
| New | +$19.7M | 0.12% | 151 |
|
|
2023
Q1 | – | Sell |
-51,897
| Closed | -$7.93M | – | 3840 |
|
|
2022
Q4 | $8.39M | Buy |
51,897
+46,358
| +837% | +$7.11M | 0.05% | 607 |
|
|
2022
Q3 | $743K | Buy |
5,539
+684
| +14% | +$98.2K | ﹤0.01% | 2870 |
|
|
2022
Q2 | $744K | Sell |
4,855
-61,314
| -93% | -$9.37M | ﹤0.01% | 2717 |
|
|
2022
Q1 | $10.7M | Buy |
66,169
+52,788
| +394% | +$7.67M | 0.09% | 270 |
|
|
2021
Q4 | $1.81M | Sell |
13,381
-50,009
| -79% | -$5.91M | 0.02% | 1461 |
|
|
2021
Q3 | $6.84M | Sell |
63,390
-27,254
| -30% | -$3.11M | 0.09% | 316 |
|
|
2021
Q2 | $10.2M | Buy |
90,644
+21,186
| +31% | +$2.39M | 0.12% | 206 |
|
|
2021
Q1 | $7.52M | Buy |
69,458
+64,072
| +1,190% | +$6.85M | 0.1% | 269 |
|
|
2020
Q4 | $577K | Sell |
5,386
-140,197
| -96% | -$13.5M | 0.01% | 1694 |
|
|
2020
Q3 | $12.8M | Buy |
145,583
+82,674
| +131% | +$7.78M | 0.19% | 83 |
|
|
2020
Q2 | $6.18M | Sell |
62,909
-26,046
| -29% | -$2.29M | 0.11% | 247 |
|
|
2020
Q1 | $6.78M | Sell |
88,955
-107,909
| -55% | -$9.19M | 0.18% | 117 |
|
|
2019
Q4 | $17.4M | Sell |
196,864
-40,942
| -17% | -$3.4M | 0.32% | 30 |
|
|
2019
Q3 | $18M | Buy |
237,806
+142,072
| +148% | +$9.74M | 0.36% | 30 |
|
|
2019
Q2 | $6.96M | Buy |
95,734
+51,497
| +116% | +$4.05M | 0.13% | 200 |
|
|
2019
Q1 | $3.56M | Buy |
44,237
+40,412
| +1,057% | +$3.31M | 0.12% | 230 |
|
|
2018
Q4 | $353K | Sell |
3,825
-27,693
| -88% | -$2.44M | 0.02% | 1168 |
|
|
2018
Q3 | $2.98M | Sell |
31,518
-11,512
| -27% | -$1.09M | 0.16% | 116 |
|
|
2018
Q2 | $3.99M | Buy |
43,030
+3,450
| +9% | +$337K | 0.2% | 101 |
|
|
2018
Q1 | $3.75M | Sell |
39,580
-3,309
| -8% | -$363K | 0.22% | 97 |
|
|
2017
Q4 | $4.15M | Buy |
42,889
+27,351
| +176% | +$2.58M | 0.22% | 67 |
|
|
2017
Q3 | $1.38M | Sell |
15,538
-37,798
| -71% | -$2.88M | 0.08% | 288 |
|
|
2017
Q2 | $3.87M | Buy |
53,336
+45,079
| +546% | +$3.03M | 0.25% | 64 |
|
|
2017
Q1 | $538K | Sell |
8,257
-24,271
| -75% | -$1.53M | 0.04% | 601 |
|
|
2016
Q4 | $2.04M | Buy |
32,528
+16,184
| +99% | +$988K | 0.16% | 143 |
|
|
2016
Q3 | $1.03M | Buy |
+16,344
| New | +$1.06M | 0.07% | 404 |
|
|
2016
Q2 | – | Sell |
-9,499
| Closed | -$543K | – | 1695 |
|
|
2016
Q1 | $543K | Buy |
+9,499
| New | +$529K | 0.03% | 716 |
|
|
2015
Q4 | – | Sell |
-66,278
| Closed | -$3.61M | – | 1733 |
|
|
2015
Q3 | $3.61M | Sell |
66,278
-16,122
| -20% | -$1.05M | 0.18% | 88 |
|
|
2015
Q2 | $5.54M | Buy |
82,400
+67,328
| +447% | +$4.4M | 0.27% | 57 |
|
|
2015
Q1 | $882K | Sell |
15,072
-11,920
| -44% | -$720K | 0.04% | 635 |
|
|
2014
Q4 | $1.77M | Sell |
26,992
-34,135
| -56% | -$2.15M | 0.1% | 295 |
|
|
2014
Q3 | $3.53M | Buy |
61,127
+35,224
| +136% | +$1.96M | 0.22% | 99 |
|
|
2014
Q2 | $1.46M | Buy |
+25,903
| New | +$1.36M | 0.09% | 339 |
|
Other funds holding ABBV
Cubist Systematic Strategies's ABBV Position: Q3 2025 in Review
Cubist Systematic Strategies sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 478,201 shares — an estimated $97.4M sold.
Cubist Systematic Strategies first reported a position in ABBV in Q2 2014 and held it in 37 quarters. The position peaked at $88.8M in Q2 2025. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.
- Cubist Systematic Strategies reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 478,201 AbbVie shares in Q3 2025, an estimated $97.4M.
- Cubist Systematic Strategies first reported a position in AbbVie in Q2 2014 and held it in 37 quarters.
- Cubist Systematic Strategies's AbbVie position peaked at $88.8M in Q2 2025.
- 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.